This week in medical device regulatory news: updated guidance on MDR requirements for legacy devices, China released new product guidelines, revised UK guidance on Conditional Marketing Authorizations, and more.
On October 14, 2024, the National Medical Products Administration (NMPA) released the 2023 revised "Registration Review Guidelines for Imaging Ultrasound Diagnostic Devices (Class III)." This update aims to improve regulatory compliance and streamline the management of ultrasound diagnostic equipment for manufacturers.
On October 17, 2024, the NMPA followed with the release of the 2024 revised "Guiding Principles for Registration and Review of Breast Implant Products." The new guidelines enhance regulatory standards to ensure the safety and quality of breast implant products. Both guidelines are now available for download.
Learn more about China Medical Device Registration & Approval.
The Medical Device Coordination Group (MDCG) has released an updated document (MDCG 2021-25 rev.1) regarding the application of Medical Device Regulation (MDR) requirements to "legacy devices" and those placed on the market before May 26, 2021. Following the amendments of Regulation (EU) 2023/607, the transitional period has been extended to December 31, 2027, or December 31, 2028, based on device risk classification. This document offers essential guidance on the applicability of MDR requirements and includes a table outlining which requirements apply to legacy devices.
Learn more about EU Medical Device Registration.
The Medicines and Healthcare products Regulatory Agency (MHRA) has released updated guidance regarding Conditional Marketing Authorisations (CMAs), exceptional circumstances Marketing Authorisations, and national scientific advice, with the latest revision published on October 18, 2024. This guidance outlines the criteria and application processes for CMAs, particularly for products addressing unmet medical needs, and details the exceptional circumstances under which marketing authorisations can be granted. The document also provides information on the national scientific advice service available to developers and marketing authorisation holders. For more details, refer to the full guidance on the MHRA website.
Learn more about MHRA UK Medical Device Registration & Approval.
On October 21, 2024, ANVISA announced the implementation of a new list of subject codes for primary petitions related to clinical trials involving experimental advanced therapy products (ATPs). This change is in line with the new Clinical Research Law (Law 14,874/2024) and aims to streamline the screening and analysis process for these trials. The updated subject codes will enhance the efficiency of document management within the Datavisa system and ensure compliance with a 90-day deadline for health analysis. The reform responds to the increasing volume of clinical trial petitions and emphasizes the agency's commitment to regulatory quality and participant safety.
Learn more about ANVISA Brazil Medical Device Registration.
Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.
Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.
Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.
.png)
As 2024 comes to a close, Pure Global proudly reflects on a transformative year marked by substantial growth, cutting-edge innovation, and impactful collaborations.
IVD manufacturers cite the new classification system, detailed definitions for intended purposes, and the need for verification of clinical evidence as key challenges under the IVDR.
(3).png)
On October 23, the European Parliament adopted a resolution revising specific elements of the Medical Devices Regulation (MDR) and the In Vitro Diagnostic Devices Regulation (IVDR). This resolution intends to address ongoing challenges in implementing the regulations by 2025 and to improve patient access to important medical products.
Multilingual documentation presents ongoing compliance and logistical hurdles for MedTech manufacturers. Transla.Ai is an industry-specific translation tool that can accelerate and streamline the translation process.